USOR 24221 - STAR Ph3 study of mavorixafor in sbjcts with neutropenic disorders w/ recurrent serious infections

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infection

Disease Types: Hematology

Available at: Arlington Heights, Niles, Chicago